ClinicalTrials.gg
RecruitingNCT06969937NektarUpdated Dec 5, 2025

Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder

A Phase 2 interventional study of Ketamine and Real-time fMRI Neurofeedback Training in Alcohol Abuse/Dependence, Alcohol Use Disorder (AUD) and Alcoholism, sponsored by Dr. med. Marcus Herdener. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Dr. med. Marcus Herdener · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing ketamine in Alcoholism — 5 open to participants now, 5 under way, none of them phase 3. Ketamine · Alcoholism.

Planned enrollment
Largest of 10
75 · median 32
Started
2025
with 3 others
Phase 2
4 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Dr. med. Marcus Herdener

Among the 10 studies testing ketamine in Alcoholism, this one has the largest planned enrollment, is one of 4 that started in 2025, is one of 4 in phase 2, and was the 9th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

5 of the 10 studies testing ketamine in Alcoholism are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ketamine in Alcoholism, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the effects of the combination of ketamine and realtime functional magnetic resonance imaging (fMRI) neurofeedback training on the treatment of individuals with alcohol use disorder (AUD). The main questions the investigators aim to answer are:

  • Can the investigators observe a positive, significant therapeutic effect by comparing changes in alcohol use via i) mean alcohol use per day, ii) heavy drinking days one month after the last treatment intervention?
  • Are changes in glutamatergic neurotransmission in the nucleus accumbens related to cue-induced cravings in individuals with AUD?
  • Is there a significant, ketamine-dependent change in glutamate levels in the nucleus accumbens?

Participants will be given ketamine or placebo and real-time fMRI neurofeedback (rt-fMRI NFT) or sham rt-fMRI NFT.

The investigators will compare three intervention groups to investigate the effects of the stand-alone effects as well as potential synergies between the combination of pharmacological and non-pharmacological intervention.

Read the detailed description

For decades, addiction research has focused predominantly on the dopaminergic system. However, preclinical research suggests that alterations of glutamatergic neurotransmission within the nucleus accumbens (NAcc) are crucial for cue-induced drug-seeking behavior, at least in animal models of addiction (Kalivas, 2009). In line with this, three randomized controlled trials have been conducted exploring ketamine as a treatment for alcohol use disorder (AUD) or harmful drinking, each combining ketamine with either memory retrieval destabilization procedures or psychological therapy (Dakwar et al., 2020a; Das et al., 2019a; Grabski et al., 2022a). While ketamine consistently reduced alcohol use in these studies, the variability in treatment responses highlights the need for further investigation into the role of the glutamate system in AUD as well as optimal treatment approaches that maximize safety and efficacy for patients.

Given the significant need to advance both mechanistic and clinical understanding of AUD, this study aims to: (1) explore the role of glutamatergic neurotransmission in AUD; (2) determine whether ketamine can modulate potentially pathophysiological altered glutamate neurotransmission, and how such modulation may be influenced by ketamine metabolism ; and (3) optimize ketamine as a treatment for AUD by leveraging synergies between the additional biological mechanism of action of ketamine (i.e., induced neuroplasticity) and a targeted non-pharmacological neuromodulatory intervention, such as neurofeedback training (NFT), to maximize clinical outcomes.

To evaluate both the mechanistic and therapeutic effects of a single ketamine infusion and rt-fMRI NFT as well as their combined application on AUD, we will assess glutamatergic signalling in the NAcc, changes in neuroplasticity via BDNF, inter-individual differences in the metabolism of ketamine, and clinical symptoms in individuals with AUD.

Therefore, in this randomized, placebo-controlled, double blind, parallel group, single centre study we investigate the extend to which a single administration of ketamine and neurofeedback training, as well as the combination of the two interventions can restore neurobiological changes related to alcoholism and what effect this new treatment method has on the symptoms of AUD.

03

Conditions studied

  • Alcohol Abuse/Dependence
  • Alcohol Use Disorder (AUD)
  • Alcoholism

Browse trials for

Keywords

  • Alcohol Use Disorder
  • Alcoholism
  • Alcohol Dependence
  • Ketamine
  • Glutamate
  • Placebo-controlled
  • Neurofeedback Training
  • Realtime fMRI
  • Therapeutic effects
  • Mechanistic effects
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • In- and outpatients aged 18 to 65 years of all sexes.
  • diagnosis of alcohol use disorder (mild - severe).
  • Motivation to reduce or stop alcohol use
  • Normal level of language comprehension (German or Swiss-German)
  • Good physical health with no unstable medical conditions
  • Participants of must use an effective and established method of for the entire study duration
  • Comply with the study protocol as explained by investigator

Exclusion criteria

Exclusion Criteria:

  • History of severe drug dependence other than alcohol (except for caffeine or nicotine) and any opiod use disorder within two months prior to enrolment.
  • Hallucinogen and ketamine use 3 months prior to study participation (including regular microdosing).
  • Alcohol withdrawal symptoms at any of the treatment visits (V2 and V3) (CIWA-Ar Scale >9).
  • Current or lifetime psychotic disorders
  • History of severe substance-induced psychosis
  • Current or lifetime bipolar I or II disorders
  • Current suicidality
  • Previous suicide attempts during the last 2 years
  • High risk of adverse emotional and behavioral reactions
  • Unmedicated or unstable hypertension
  • Severe illness (e. g. myocardial ischemia or arrythmias, severe pulmonary secretions, glaucoma, congestive heart failure or angina, significant renal or hepatic impairment)
  • Acute infection (e. g. pulmonary or upper respiratory tract infection)
  • Insufficient treated or uncorrected hyperthyroidism
  • Severe central nervous system related traumas or disorders (e. g. stroke, cerebral trauma with loss of consciousness over more than 24h, epilepsy)
  • During the study, new use or dose changes of already existing concomitant medication without prior informing the investigators.
  • Taking medications that are known to modualte uridine diphosphate glucuronosyltransferase-enzyme
  • Medication directly affecting glutamate signaling (e. g. anticonvulsant medication)
  • Inhibitors of UGT1A9 and 1A10 should be discontinued at least five half-lives prior to the administration of ketamine.
  • Monoamine oxidase and aldehyde or alcohol dehydrogenase inhibitors should be discontinued at least 5 half-lives prior to the dose of ketamine.
  • Pregnancy or lactation
  • Women of with no use of medically accepted (e. g. condoms, contraceptive diaphragm, birth control pill, hormone injection, intrauterine device)
  • \< 17 or > 35
  • Allergy, , or other adverse reaction to previous use of ketamine
  • Contradictions to magnetic resonance imaging
  • Concurrent participation in other clinical study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    rt-fMRI NFT / Ketamine

    Participants get real time neurofeedback based on an experimental regions' activity and receive 0.8 mg ketamine (i.v.) per kilogram bodyweight.

    Drug: Ketamine · Behavioral: Real-time fMRI Neurofeedback Training

  • Experimental
    sham rt-fMRI NFT / Ketamine

    Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive 0.8 mg ketamine (i.v.) per kilogram bodyweight.

    Drug: Ketamine · Behavioral: Sham Neurofeedback Training/ Ketamine

  • Experimental
    rt-fMRI NFT / Placebo

    Participants get real time neurofeedback based on an control regions' activity and receive a 0.9% NaCL infusion (placebo).

    Behavioral: Real-time fMRI Neurofeedback Training · Drug: Placebo

Interventions

  • A single dose of ketamine 0.8 mg ketamine (i.v.) per kilogram bodyweight

  • BehavioralReal-time fMRI Neurofeedback Training

    Participants will undergo a closed-loop rt-fMRI paradigm over 25 minutes. Participants will be instructed to use strategies to downregulate cue-induced cravings. The Intensity of cues will adjust based on the participants neural activity in response to cues. This dynamic feedback mechanism allows for personalized training aimed at improving the participant's ability to manage cravings.

  • DrugPlacebo

    Single dose of placebo (0.9% NaCl infusion)

  • BehavioralSham Neurofeedback Training/ Ketamine

    Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive 0.8 mg ketamine (i.v.) per kilogram bodyweight. The use of sham-NFT allows for a rigorous assessment of the specific effects of combined rt-fMRI NFT and ketamine by controlling for non-specific factors such as expectancy effects or the therapeutic context.

06

What researchers measure

Primary outcomes

  1. Change in mean alcohol use per day

    Change in mean alcohol use per day. Alcohol use is measured via a combination of the digital app and the Timeline Follow-Back Questionnaire.

    Time frame: Starting immediately after the intervention visit 2 and ending 4 weeks later (integration visit).

  2. Change in heavy drinking days

    Change in heavy drinking days. Defined as five or more standard units of alcohol in a day for a man and four or more standard units of alcohol in a day for a woman. Alcohol use is measured via a combination of the digital app and the Timeline Follow-Back Questionnaire.

    Time frame: Starting immediately after the intervention visit 2 and ending 4 weeks later (integration visit).

Secondary outcomes

  1. Changes in glutamat levels during craving

    Changes in glutamatergic signalling in the NAcc measured via Magnetic Resonance Spectroscopy (MRS) during craving vs neutral cue exposure.

    Time frame: During the intervention visit 1a and 1 week later during the intervention visit 2.

  2. Changes in Brain Derived Neurotrophic Factor

    Treatment-induced changes in neuroplasticity assessed using the brain derived neurotrophic factor (BDNF) through blood analysis.

    Time frame: During the intervention visit 2 at baseline 30 minutes before and 2 hours after infusion start.

  3. Individual variations in ketamine pharmacokinetics

    Changes in ketamine plasma concentrations and its metabolites measured via blood samples taken.

    Time frame: During the intervention visit 2 at baseline, 45 minutes, 1 hour 30 minutes before, and 2 hours 30 minutes after infusion start.

  4. Predictive value of baseline rs-fMRI for treatment response

    Predictive value of rs-fMRI for treatment response assessed via the two primary outcomes

    Time frame: Between 1 and 2 weeks after baseline (screening visit) during the intervention visit 1a.

  5. Changes in alcohol use in blood alcohol metabolites

    Blood samples will be collected to analyse markers of alcohol use. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT) and Phosphatidyl Ethanol (PEth) will be analysed from blood samples.

    Time frame: At baseline (screening visit) and 4 weeks later (integration visit).

  6. Severity of alcohol use disorder

    Changes in severity of alcohol use disorder score assessed by the Obsessive Compulsive Drinking Scale, ranging from 0 to 56, where higher scores indicate more compulsive behaviors and obsessive thoughts to use alcohol.

    Time frame: From baseline (screening visit) until 6 months later (follow-up survey II).

  7. Changes in alcohol abstinence ability

    Changes in individuals confidence in their ability to abstain from alcohol in high risk situations assessed with the Alcohol Abstinence Self-Efficacy Scale, ranging from 0 to 160, where higher scores indicate higher self-confidence in the ability to avoid drinking.

    Time frame: From baseline (screening visit) until 6 months later (follow-up survey II).

  8. Experience of alcohol craving

    The Visual Analogue Scale for Alcohol Craving on a scale ranging from 0 to 100, where higher scores indicate higher subjective experience of craving.

    Time frame: From baseline (screening visit) until 6 months later (follow-up survey II).

  9. Depressive symptoms

    Changes in depressive symptoms measured with Beck Depression Inventory. The scale ranges from 0 to 63 where higher scores indicate more severe depressive symptoms.

    Time frame: From baseline (screening visit) until 6 months later (follow-up survey II).

  10. Experience of pleasure across different domains

    Changes in the experience of pleasure across different domains assessed by the Domains of Pleasure Scale, ranging from 0 to 210, where a higher score indicates a higher experience of pleasure.

    Time frame: From baseline (screening visit) until 6 months later (follow-up survey II).

  11. Hedonic capacity

    Changes in hedonic capacity measured by the Trait Hedonic Capacity Scale, ranging from 16 to 80, where a higher score indicates a higher hedonic capacity.

    Time frame: From baseline (screening visit) until 6 months later (follow-up survey II).

  12. Perceived quality of life

    Changes in the perceived quality of life assessed with the Quality of Life Scale, ranging from 0 to 400, whereas higher scores indicate higher perceived quality of life.

    Time frame: From baseline (screening visit) until 6 months later (follow-up survey II).

  13. Posttraumatic stress symptoms

    Changes in posttraumatic stress symptoms measured with Posttraumatic Stress Disorder Checklist for DSM-5. The scale ranges from 0 to 80, where higher scores indicate more severe posttraumatic stress symptoms.

    Time frame: From baseline (screening visit) until 6 months later (follow-up survey II).

  14. Perceived stress

    Changes in perceived stress assessed with a subscale of the Stress \& Coping Inventory, ranging from 21 to 147, where higher scores indicate higher perceived stress.

    Time frame: From baseline (screening visit) until 6 months later (follow-up survey II).

  15. Subjective effects of ketamine infusion

    Assess the acute subjective effects of the infusion with the Five-Dimension Altered State of Consciousness Questionnaire (5D-ASC), ranging from 0 to 100, where higher scores indicate the occurence of altered states of consciousness.

    Time frame: 2 hours after the ketamine infusion (intervention visit 2).

  16. Effects of ketamine infusion on mystic experiences

    Assess the acute subjective effects of the infusion with the Hood's Mysticism Scale, ranging from 20 to 100 where higher scores indicate the occurence of mystic experiences.

    Time frame: 2 hours after the ketamine infusion (intervention visit 2).

  17. Neurofeedback Experience

    The Neurofeedback Post Questionnaire (NF-PostQ) asks participants about their used strategies and experiences during neurofeedback training.

    Time frame: After neurofeedback training (intervention visit 1b) and up to two weeks later (intervention visit 2).

  18. Daily alcohol use and craving

    A Digital app (SEMA3) will document daily alcohol craving and alcohol use using an Ecological Momentary Assessment method.

    Time frame: From baseline (screening visit) up to 5 months later (one month prior to follow-up survey II).

  19. Alcohol use in urine alcohol metabolites

    Changes in alcohol metabolites via urine analyses as objective measure of alcohol use.

    Time frame: From baseline (screening visit) up to one month later (Integration visit)

07

Study locations

1 of 1 sites recruiting
  • Psychiatric University Zurich, University of Zurich
    Zurich, 8032, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Our data will be published on the website of Open Science Framework.

Supporting information: Study protocol, Informed consent form

Time frame: After the publication of our data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 18 months is below that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 14, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06969937
Lead sponsor
Dr. med. Marcus Herdener
Responsible party
Dr. med. Marcus Herdener (Principal Investigator, Head of Center for Addictive Disorders, Psychiatric University Hospital, Zurich) — Sponsor-investigator
First posted
May 14, 2025
Start date
Jun 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 5, 2025

Study contacts

Marcus Herdener, PD Dr. med.
Contact
marcus.herdener@bli.uzh.ch
+41583845810
Etna Engeli, Dr.
Contact
etna.engeli@bli.uzh.ch
+41583842771 ext. +41583842771

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion